Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Abstract

In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.).

Keywords

CanagliflozinMedicineType 2 diabetesDiabetes mellitusDiabetic nephropathyNephropathyDapagliflozinInternal medicineClinical trialType 2 Diabetes MellitusEndocrinologyIntensive care medicinePharmacologyUrology

MeSH Terms

AgedCanagliflozinCardiovascular DiseasesCreatinineDiabetes MellitusType 2Diabetic NephropathiesDouble-Blind MethodFemaleFollow-Up StudiesGlomerular Filtration RateHumansKidney FailureChronicMaleMiddle AgedSodium-Glucose Transporter 2 Inhibitors

Affiliated Institutions

Related Publications

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J.L. Heerspink , Bergur V. Stefánsson , Ricardo Correa‐Rotter +11 more

Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50...

2020 New England Journal of Medicine 4549 citations

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott , Itamar Raz , Marc P. Bonaca +17 more

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...

2018 New England Journal of Medicine 5890 citations

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray , Scott D. Solomon , Silvio E. Inzucchi +35 more

BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through ...

2019 New England Journal of Medicine 6238 citations

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer , Nizar M. Tannir , Ray McDermott +29 more

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

2018 New England Journal of Medicine 4403 citations

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer , Stefan D. Anker , Javed Butler +36 more

Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure th...

2020 New England Journal of Medicine 4558 citations

Publication Info

Year: 2019
Type: article
Volume: 380
Issue: 24
Pages: 2295-2306
Citations: 5513
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

5513

OpenAlex

281

Influential

4885

CrossRef

Cite This

APA Style

                            
                                
                                    Vlado Perkovic, 
                                
                                    Meg Jardine, 
                                
                                    Bruce Neal
                                
                                et al.
                            
                            (2019). 
                            Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. 
                            New England Journal of Medicine
                            , 380
                            (24)
                            , 2295-2306.
                            https://doi.org/10.1056/nejmoa1811744
                        

Identifiers

DOI: 10.1056/nejmoa1811744
PMID: 30990260

Data Quality

Data completeness: 90%